EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 58 / No 2 (June 2026) J Extra Corpor Technol, 58 2 (2026) 164-171 References
Open Access
Review
Issue
J Extra Corpor Technol
Volume 58, Number 2, June 2026
Page(s) 164 - 171
DOI https://doi.org/10.1051/ject/2026002
Published online 19 June 2026
  1. Teoh KH, Young E, Blackall MH, et al. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;128:211–219. [CrossRef] [PubMed] [Google Scholar]
  2. Taneja R, Marwaha G, Sinha P, et al. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery. Can J Anaesth. 2009;56:489–496. [CrossRef] [PubMed] [Google Scholar]
  3. Ichikawa J, Kodaka M, Nishiyama K, et al. Reappearance of circulating heparin in whole blood heparin concentration-based management does not correlate with postoperative bleeding after cardiac surgery. J Cardiothorac Vasc Anesth. 2014;28:1003–1007. [CrossRef] [PubMed] [Google Scholar]
  4. Boer C, Meesters MI, Veerhoek D, et al. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth. 2018;120:914–927. [CrossRef] [PubMed] [Google Scholar]
  5. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg. 1995;110:36–45. [CrossRef] [PubMed] [Google Scholar]
  6. Koster A, Börgermann J, Gummert J, et al. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost. 2014;20:290–295. [CrossRef] [PubMed] [Google Scholar]
  7. Meesters MI, Veerhoek D, de Lange F, et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. Thromb Haemost. 2016;116:251–261. [CrossRef] [PubMed] [Google Scholar]
  8. Kunz SA, Miles LF, Ianno DJ, et al. The effect of protamine dosing variation on bleeding and transfusion after heparinisation for cardiopulmonary bypass. Perfusion. 2018;33:445–452. [CrossRef] [PubMed] [Google Scholar]
  9. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781–785. [CrossRef] [PubMed] [Google Scholar]
  10. Abuelkasem E, Mazzeffi MA, Henderson RA, et al. Clinical impact of protamine titration-based heparin neutralization in patients undergoing coronary bypass grafting surgery. J Cardiothorac Vasc Anesth. 2019;33:2153–2160. [CrossRef] [PubMed] [Google Scholar]
  11. Lindblad B, Wakefield TW, Whitehouse WM, et al. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg. 1988;22:55–59. [CrossRef] [PubMed] [Google Scholar]
  12. Ammar T, Fisher CF. The effects of heparinase 1 and protamine on platelet reactivity. Anesthesiology. 1997;86:1382–1386. [CrossRef] [PubMed] [Google Scholar]
  13. Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;118:354–360. [CrossRef] [PubMed] [Google Scholar]
  14. Hattersley PG. Activated coagulation time of whole blood. Jama. 1966;196:436–440. [Google Scholar]
  15. Jones K, Nasrallah F, Darling E, et al. The in vitro effects of aprotinin on twelve different ACT tests. Ject. 2004;36:51–57. [Google Scholar]
  16. Li H, Serrick C, Rao V, Yip PM. A comparative analysis of four activated clotting time measurement devices in cardiac surgery with cardiopulmonary bypass. Perfusion. 2021;36:610–619. [Google Scholar]
  17. Finley A, Greenberg C. Heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg. 2013;116:1210–1222. [CrossRef] [PubMed] [Google Scholar]
  18. Finley A. Heparin sensitivity and resistance: management during cardiopulmonary bypass. ASA Refresher Courses Anesthesiol. 2015;43:58–65. [Google Scholar]
  19. Lobato RL, Despotis GJ, Levy JH, et al. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg. 2010;139:1665–1666. [Google Scholar]
  20. Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. PNAS. 1989;86:3619–3623. [Google Scholar]
  21. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391. [CrossRef] [PubMed] [Google Scholar]
  22. Despotis GJ, Joist JH, Hogue Jr CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation: a prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46–54. [CrossRef] [PubMed] [Google Scholar]
  23. Despotis GJ, Joist JH, Hogue Jr CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost. 1996;76:902–908. [Google Scholar]
  24. Dirkmann D, Nagy E, Britten MW, Peters J. Point-of-care measurement of activated clotting time for cardiac surgery as measured by the Hemochron signature elite and the Abbott i-STAT: agreement, concordance, and clinical reliability. BMC Anesthesiol. 2019;19:1–8. [Google Scholar]
  25. Thompson TZ, Kunak RL, Savage NM, Agarwal S, Chazelle J, Singh G. Intraoperative monitoring of heparin: Comparison of activated coagulation time and whole blood heparin measurements by different point-of-care devices with heparin concentration by laboratory-performed plasma anti-Xa assay. Lab Med. 2019;50:348–356. [Google Scholar]
  26. Lee JM, Park EY, Kim KM, Won JC, Jung TK, Lee SK. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution. J Int Med Res. 2018;46:873–882. [Google Scholar]
  27. Vranken NP, Theelen AJ, Orbons T, Barenbrug PJ, Weerwind PW. Point-of-care measurement of kaolin activated clotting time during cardiopulmonary bypass: A single sample comparison between ACT plus and i-STAT. J Extra Corpor Technol. 2021;53:57. [Google Scholar]
  28. Comunale ME, Maslow A, Robertson LK, Haering JM, Mashikian JS, Lowenstein E. Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction. J Cardiothorac Vasc Anesth. 2003;17:309–313. [CrossRef] [PubMed] [Google Scholar]
  29. Mclaughlin KE, Dunning J. In patients post cardiac surgery do high doses of protamine cause increased bleeding? Interact Cardiovasc Thorac Surg. 2003;2:424–426. [CrossRef] [PubMed] [Google Scholar]
  30. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103:192–196. [CrossRef] [PubMed] [Google Scholar]
  31. De Simone F, Nardelli P, Licheri M, et al. Less is more: We are administering too much protamine in cardiac surgery. Ann Card Anaesth. 2021;24:178–182. [CrossRef] [PubMed] [Google Scholar]
  32. Valchanov K, Falter F, George S, et al. Three cases of anaphylaxis to protamine: management of anticoagulation reversal. J Cardiothorac Vasc Anesth. 2019;33:482–486. [CrossRef] [PubMed] [Google Scholar]
  33. Hecht P, Besser M, Falter F. Are We Able to Dose Protamine Accurately Yet? A Review of the Protamine Conundrum. J Extra Corpor Technol. 2020;52:63–70. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. Cuenca JS, Diz PG, Sampedro FG, Zincke JM, Acuña HR, Fontanillo MM. Method to calculate the protamine dose necessary for reversal of heparin as a function of activated clotting time in patients undergoing cardiac surgery. J Extra Corpor Technol. 2013;45:235. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  35. Davidsson FÖ, Johagen D, Appelblad M, Svenmarker S. Reversal of heparin after cardiac surgery: protamine titration using a statistical model. J Cardiothorac Vasc Anesth. 2015;29:710–714. [CrossRef] [PubMed] [Google Scholar]
  36. Suelzu S, Cossu A, Pala G, et al. Impact of different dosage of protamine on heparin reversal during off-pump coronary artery bypass: a clinical study. Heart Lung Vessel. 2015;7:238. [PubMed] [Google Scholar]
  37. Meesters MI, Veerhoek D, de Jong JR, Boer C. A pharmacokinetic model for protamine dosing after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2016;30:1190–1195. [CrossRef] [PubMed] [Google Scholar]
  38. Hällgren O, Svenmarker S, Appelblad M. Implementing a statistical model for protamine titration: effects on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2017;31:516–521. [CrossRef] [PubMed] [Google Scholar]
  39. Goedhart AL, Gerritse BM, Rettig TC, et al. A 0.6-protamine/heparin ratio in cardiac surgery is associated with decreased transfusion of blood products. Interact Cardiovasc Thorac Surg. 2020;31:391–397. [CrossRef] [PubMed] [Google Scholar]
  40. Miles LF, Burt C, Arrowsmith J, et al. Optimal protamine dosing after cardiopulmonary bypass: The PRODOSE adaptive randomised controlled trial. PLoS Med. 2021;18:e1003658. [Google Scholar]
  41. Khan JH, Green EA, Chang J, et al. Blood and blood product conservation: results of strategies to improve clinical outcomes in open heart surgery patients at a tertiary hospital. J Extra Corpor Technol. 2017;49:273–282. [Google Scholar]
  42. Khan JH, Barkin MS, Stanton J, Khan A, Stanten RD. Blood and blood product conservation: results of strategies to improve clinical outcomes in open heart surgery patients at a tertiary hospital are maintained 4 years after initiation. J Extra Corpor Technol. 2022;54:35. [Google Scholar]
  43. Vespe MW, Stone ME, Lin HM, Ouyang Y. Accurate protamine: heparin matching (not just smaller protamine doses) decreases postoperative bleeding in cardiac surgery; results from a high-volume academic medical center. Perfusion. 2024 Oct;39(7):1335–1347. [Google Scholar]
  44. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685–689. [CrossRef] [PubMed] [Google Scholar]
  45. Noui N, Zogheib E, Walczak K, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion. 2012;27:214–220. [CrossRef] [PubMed] [Google Scholar]
  46. Fox DJ, Reed G. Vehicles of heparin management: a comparison. Surgery. 1979;1;1:2. [Google Scholar]
  47. Aziz KA, Masood O, Hoschtitzky JA, Ronald A. Does use of the Hepcon® point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery?. Interact Cardiovasc Thorac Surg. 2006;5:469–482. [Google Scholar]
  48. Ichikawa J, Mori T, Kodaka M, et al. Changes in heparin dose response slope during cardiac surgery: possible result in inaccuracy in predicting heparin bolus dose requirement to achieve target ACT. Perfusion. 2017;32:474–480. [Google Scholar]
  49. Manual O. Hepcon® HMS Plus Hemostasis Management System. Multichannel Clot Timing Instrument With Automated Pipetting:116. [Google Scholar]
  50. Lee MH, Riley W. Factors associated with errors in the heparin dose response test: Recommendations to improve individualized heparin management in cardiopulmonary bypass. Perfusion. 2021;36:513–523. [CrossRef] [PubMed] [Google Scholar]
  51. Lee MH, Riley W, Shann KG. Can the minimum protamine dose to neutralize heparin at the completion of cardiopulmonary bypass be significantly lower than the conventional practice? J Extra Corpor Technol. 2021;53:170–176. [PubMed] [Google Scholar]
  52. Lee MH, Beck M, Shann K. Protamine dose to neutralize heparin at the completion of cardiopulmonary bypass can be reduced significantly without affecting post-operative bleeding. J Extra Corpor Technol. 2023;55:105–111. [Google Scholar]
  53. Garvin S, Fitzgerald D, Muehlschlegel JD, et al. Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg. 2010;111:856. [Google Scholar]
  54. Raner G, Hu Y, Trowbridge C, et al. Comparison of blood concentration and weight-based heparin and protamine dosing strategies for cardiopulmonary bypass: A systematic review and meta-analysis. Cureus. 2024;16. [Google Scholar]
  55. Bartoszko J, Karkouti K. Managing the coagulopathy associated with cardiopulmonary bypass. J Thromb Haemost. 2021;19:617–632. [CrossRef] [PubMed] [Google Scholar]
  56. Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology. 2002;97:837–841. [CrossRef] [PubMed] [Google Scholar]
  57. Ranucci M, Baryshnikova E, Ciotti E, Ranucci M, Silvetti S, Surgical and Clinical Outcome REsearch (SCORE) Group. Hemodilution on cardiopulmonary bypass: thromboelastography patterns and coagulation-related outcomes. J Cardiothorac Vasc Anesth. 2017;31:1588–1594. [Google Scholar]
  58. Höfer J, Fries D, Solomon C, Velik-Salchner C, Ausserer J. A snapshot of coagulopathy after cardiopulmonary bypass. Clin Appl Thromb Hemost. 2016;22:505–511. [Google Scholar]
  59. Canver CC, Kroncke GM, Nichols RD, Murray EL, Mentzer Jr RM. The effects of intraoperative autologous whole blood sequestration on the need for transfusion of allogenic blood and blood products in coronary bypass operations. J Cardiovasc Surg. 1995;36:423–428. [Google Scholar]
  60. Stover EP, Siegel LC, Hood PA, O’Riordan GE, McKenna TR. Platelet-rich plasma sequestration, with therapeutic platelet yields, reduces allogeneic transfusion in complex cardiac surgery. Anesth Analg. 2000;90:509–516. [Google Scholar]
  61. Butt SP, Kakar V, Kumar A, et al. Heparin resistance management during cardiac surgery: a literature review and future directions. J Extra Corpor Technol. 2024;56:136–144. [Google Scholar]
  62. Knapik P, Cieśla D, Przybylski R, Knapik T. The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery. Med Sci Monit. 2012;18:CR283–CR289. [Google Scholar]
  63. Stammers AH, Francis SG, Miller R, et al. Application of goal-directed therapy for the use of concentrated antithrombin for heparin resistance during cardiac surgery. Perfusion. 2021;36:171–182. [CrossRef] [PubMed] [Google Scholar]
  64. Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins. Thromb. Haemost. 1993;70:625–630. [Google Scholar]
  65. Stone ME, Vespe MW. Heparin rebound: An in-depth review. J Cardiothorac Vasc Anesth. 2023;37:601–612. [Google Scholar]
  66. Levy JH, Montes F, Szlam F, et al. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg. 2000; 90: 1076–1079. [Google Scholar]
  67. Butterworth J, Lin YA, Prielipp RC, et al. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74:1589–1595. [Google Scholar]
  68. Zheng A, Zhang W, Li C, et al. The heparinase-linked differential time method allows detection of heparin potency in whole blood with high sensitivity and dynamic range. Biosens Bioelectron. 2022;198:113856. [Google Scholar]
  69. Whitton TP, Healy WJ. Review of thromboelastography (TEG): medical and surgical applications. Ther Adv Pulm Crit Care Med. 2023;18:29768675231208426. [Google Scholar]
  70. Adelmann D, Hartmann J, Moore HB, et al. TEG® 6s heparin neutralization cartridge for hemostatic assessment of patients undergoing cardiovascular surgery. Anesthesiology. 2025;144:103. [Google Scholar]
  71. Foubert R, Van Vaerenbergh G, Cammu G, Buys S, et al. Protamine titration to optimize heparin antagonization after cardiopulmonary bypass. Perfusion. 2024;39:1062–1069. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.